{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:15:34Z","timestamp":1770520534440,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T00:00:00Z","timestamp":1375488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10147-013-0604-z","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T05:51:03Z","timestamp":1375422663000},"page":"693-701","source":"Crossref","is-referenced-by-count":10,"title":["Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-na\u00efve prostate cancer with bone metastasis"],"prefix":"10.1007","volume":"19","author":[{"given":"Masahiro","family":"Nozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Komura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunobu","family":"Esa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Uekado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeya","family":"Uejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,3]]},"reference":[{"key":"604_CR1","unstructured":"National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer version1 2013. Available via DIALOG. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf . Accessed Dec 2012"},{"key":"604_CR2","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897\u20137903","journal-title":"J Clin Oncol"},{"key":"604_CR3","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","volume":"26","author":"F Saad","year":"2008","unstructured":"Saad F, Adachi JD, Brown JP et al (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465\u20135476","journal-title":"J Clin Oncol"},{"key":"604_CR4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH et al (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"604_CR5","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/j.seminoncol.2010.06.008","volume":"37","author":"HL Neville-Webbe","year":"2010","unstructured":"Neville-Webbe HL, Gnant M, Coleman RE (2010) Potential anticancer properties of bisphosphonates. Semin Oncol 37(Suppl 1):S53\u2013S65","journal-title":"Semin Oncol"},{"key":"604_CR6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453\u2013475","journal-title":"Cancer Treat Rev"},{"key":"604_CR7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","volume":"16","author":"I Holen","year":"2010","unstructured":"Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16:1262\u20131271","journal-title":"Curr Pharm Des"},{"key":"604_CR8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"604_CR9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"604_CR10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"604_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195\u2013202","journal-title":"Cancer"},{"key":"604_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0304-3959(93)90049-U","volume":"53","author":"DC Turk","year":"1993","unstructured":"Turk DC, Rudy TE, Sorkin BA (1993) Neglected topics in chronic pain treatment outcome studies: determination of success. Pain 53:3\u201316","journal-title":"Pain"},{"key":"604_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1442-2042.2011.02914.x","volume":"19","author":"N Kamiya","year":"2012","unstructured":"Kamiya N, Suzuki H, Endo T et al (2012) Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19:169\u2013173","journal-title":"Int J Urol"},{"key":"604_CR14","unstructured":"Pummer K, Lehnert M, Stettner H et al (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32(Suppl3):81\u201385"},{"key":"604_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/978-1-60327-492-0_22","volume":"472","author":"T Fukagai","year":"2009","unstructured":"Fukagai T, Namiki T, Carlile RG et al (2009) Racial differences in clinical outcome after prostate cancer treatment. Methods Mol Biol 472:455\u2013466","journal-title":"Methods Mol Biol"},{"key":"604_CR16","first-page":"276","volume":"103","author":"Y Itami","year":"2012","unstructured":"Itami Y, Yamamoto Y, Nagai Y et al (2012) Clinical outcome of stage D2 prostate cancer. Jpn J Urol 103:276","journal-title":"Jpn J Urol"},{"key":"604_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/PPA.S2314","volume":"2","author":"R G\u00e1lvez","year":"2008","unstructured":"G\u00e1lvez R, Ribera V, Gonz\u00e1lez-Escalada JR et al (2008) Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Prefer Adherence 2:215\u2013224","journal-title":"Patient Prefer Adherence"},{"key":"604_CR18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","volume":"76","author":"F Saad","year":"2010","unstructured":"Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175\u20131181","journal-title":"Urology"},{"key":"604_CR19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","volume":"17","author":"KP Weinfurt","year":"2006","unstructured":"Weinfurt KP, Anstrom KJ, Castel LD et al (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986\u2013989","journal-title":"Ann Oncol"},{"key":"604_CR20","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"604_CR21","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968\u2013971","journal-title":"Haematologica"},{"key":"604_CR22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"K Zervas","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620\u2013623","journal-title":"Br J Haematol"},{"key":"604_CR23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","volume":"27","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Ning YM, Chen CC et al (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27:221\u2013226","journal-title":"Cancer Invest"},{"key":"604_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S et al (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 35:386\u2013392","journal-title":"Am J Clin Oncol"},{"key":"604_CR25","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356\u20135362","journal-title":"J Clin Oncol"},{"key":"604_CR26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"604_CR27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","volume":"18","author":"CA Migliorati","year":"2010","unstructured":"Migliorati CA, Woo SB, Hewson I et al (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18:1099\u20131106","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0604-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0604-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:37:32Z","timestamp":1559111852000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0604-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,3]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0604-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,3]]}}}